Cargando…

Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients

AIM OF THE STUDY: Intrahepatic covalently closed circular DNA (cccDNA) is the main cause of hepatitis B virus (HBV) persistence. Therefore, a noninvasive serum biomarker that can reflect intrahepatic cccDNA is required for evaluation of HBV virological, biochemical activity and therapeutic response....

Descripción completa

Detalles Bibliográficos
Autores principales: Elshayeb, Aymen Farid, Abdrabu, Mohamed Gamal, Asar, Sara Lotfy, Abdelaziz, Mohamed Adel, Abuelkheir, Hossam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122096/
https://www.ncbi.nlm.nih.gov/pubmed/34027120
http://dx.doi.org/10.5114/ceh.2021.104472
_version_ 1783692514361868288
author Elshayeb, Aymen Farid
Abdrabu, Mohamed Gamal
Asar, Sara Lotfy
Abdelaziz, Mohamed Adel
Abuelkheir, Hossam
author_facet Elshayeb, Aymen Farid
Abdrabu, Mohamed Gamal
Asar, Sara Lotfy
Abdelaziz, Mohamed Adel
Abuelkheir, Hossam
author_sort Elshayeb, Aymen Farid
collection PubMed
description AIM OF THE STUDY: Intrahepatic covalently closed circular DNA (cccDNA) is the main cause of hepatitis B virus (HBV) persistence. Therefore, a noninvasive serum biomarker that can reflect intrahepatic cccDNA is required for evaluation of HBV virological, biochemical activity and therapeutic response. Aim of the study was to assess serum hepatitis B pregenomic RNA in low viremia patients (HBV DNA < 2000 IU/ml) and high viremia (HBV DNA > 2000 IU/ml). MATERIAL AND METHODS: This study was carried out on two groups of chronic hepatitis B patients: group A – 40 patients with low viremia (HBV DNA < 2000 IU/ml); group B – 40 patients with high viremia (HBV DNA > 2000 IU/ml when diagnosed). They were assessed before treatment and after 6 months of treatment (entecavir 0.5 mg/24 h). Serum HBV pregenomic RNA was quantified using RT-PCR. RESULTS: Pregenomic RNA (pgRNA) was significantly lower in group A than in group B (before treatment). Moreover, it was significantly lower after 6 months of treatment than before treatment in group B. A significant positive correlation was observed between pgRNA and HBV DNA in groups A and B (before treatment); however, after 6 months of treatment of group B patients, although 35 patients had undetectable HBV DNA, they showed detectable levels of serum pgRNA and pgRNA > 4000 IU/ml was associated with virological and biochemical activity. CONCLUSIONS: Serum HBV pregenomic RNA might be a promising marker for assessment of HBV virological, biochemical activity and evaluating therapeutic responses.
format Online
Article
Text
id pubmed-8122096
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-81220962021-05-21 Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients Elshayeb, Aymen Farid Abdrabu, Mohamed Gamal Asar, Sara Lotfy Abdelaziz, Mohamed Adel Abuelkheir, Hossam Clin Exp Hepatol Original Paper AIM OF THE STUDY: Intrahepatic covalently closed circular DNA (cccDNA) is the main cause of hepatitis B virus (HBV) persistence. Therefore, a noninvasive serum biomarker that can reflect intrahepatic cccDNA is required for evaluation of HBV virological, biochemical activity and therapeutic response. Aim of the study was to assess serum hepatitis B pregenomic RNA in low viremia patients (HBV DNA < 2000 IU/ml) and high viremia (HBV DNA > 2000 IU/ml). MATERIAL AND METHODS: This study was carried out on two groups of chronic hepatitis B patients: group A – 40 patients with low viremia (HBV DNA < 2000 IU/ml); group B – 40 patients with high viremia (HBV DNA > 2000 IU/ml when diagnosed). They were assessed before treatment and after 6 months of treatment (entecavir 0.5 mg/24 h). Serum HBV pregenomic RNA was quantified using RT-PCR. RESULTS: Pregenomic RNA (pgRNA) was significantly lower in group A than in group B (before treatment). Moreover, it was significantly lower after 6 months of treatment than before treatment in group B. A significant positive correlation was observed between pgRNA and HBV DNA in groups A and B (before treatment); however, after 6 months of treatment of group B patients, although 35 patients had undetectable HBV DNA, they showed detectable levels of serum pgRNA and pgRNA > 4000 IU/ml was associated with virological and biochemical activity. CONCLUSIONS: Serum HBV pregenomic RNA might be a promising marker for assessment of HBV virological, biochemical activity and evaluating therapeutic responses. Termedia Publishing House 2021-03-25 2021-03 /pmc/articles/PMC8122096/ /pubmed/34027120 http://dx.doi.org/10.5114/ceh.2021.104472 Text en Copyright © 2021 Clinical and Experimental Hepatology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) )
spellingShingle Original Paper
Elshayeb, Aymen Farid
Abdrabu, Mohamed Gamal
Asar, Sara Lotfy
Abdelaziz, Mohamed Adel
Abuelkheir, Hossam
Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients
title Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients
title_full Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients
title_fullStr Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients
title_full_unstemmed Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients
title_short Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients
title_sort assessment of hepatitis b virus pregenomic rna in high and low viremic chronic hepatitis b patients
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122096/
https://www.ncbi.nlm.nih.gov/pubmed/34027120
http://dx.doi.org/10.5114/ceh.2021.104472
work_keys_str_mv AT elshayebaymenfarid assessmentofhepatitisbviruspregenomicrnainhighandlowviremicchronichepatitisbpatients
AT abdrabumohamedgamal assessmentofhepatitisbviruspregenomicrnainhighandlowviremicchronichepatitisbpatients
AT asarsaralotfy assessmentofhepatitisbviruspregenomicrnainhighandlowviremicchronichepatitisbpatients
AT abdelazizmohamedadel assessmentofhepatitisbviruspregenomicrnainhighandlowviremicchronichepatitisbpatients
AT abuelkheirhossam assessmentofhepatitisbviruspregenomicrnainhighandlowviremicchronichepatitisbpatients